FDA Says Single-Dose Shot from J&J Prevents Severe COVID

An illustration of COVID-19 by the Centers for Disease Control and Prevention.

WASHINGTON (AP) — An analysis by U.S. regulators says Johnson & Johnson’s single-dose vaccine provides strong protection against severe COVID-19.

The report Wednesday confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19.

On Friday, a panel of experts to the Food and Drug Administration will debate if the evidence is strong enough to recommend the long-anticipated shot.

The FDA is expected to make a final decision within days.

If the FDA clears the J&J shot for U.S. use, it won’t boost vaccine supplies significantly right away.

Only a few million doses are expected to be ready for shipping in the first week.

By LAURAN NEERGAARD and MATTHEW PERRONE, Associated Press
About Grady Culhane

Grady Culhane is a Cape Cod native currently living in Eastham. He studied media communications at Cape Cod Community College and joined the CapeCod.com News Center in 2019.



CapeCod.com
737 West Main Street
Hyannis, MA 02601
Contact Us | Advertise Terms of Use 
Employment and EEO | Privacy